National Health (Originator Brand) Amendment Determination 2016 (No. 5) (PB 71 of 2016) (Cth)

PB 71 of 2016

National Health (Originator Brand) Amendment Determination 2016 (No. 5)

National Health Act 1953

I, DIANNA PROSSER, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated        25^th   July 2016

______________________________________

DIANNA PROSSER

Assistant Secretary (Acting)

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2016 (No. 5).

(2)     This Determination may also be cited as PB 71 of 2016.

1. Commencement

This Determination commences on 1 August 2016.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (after table item 17)

Insert:

17A Atomoxetine Strattera

[2]   Schedule 1 (after table item 91)

Insert:

91A Follitropin Alfa Gonal-f Pen

[3]   Schedule 1, table item 156 (entry for morphine)

Insert as first item, in the columns in the order indicated:

Hospira Pty Limited Injection

[4]   Schedule 1 (after table item 229)

Insert:

229A	Tobramycin	Hospira Pty Limited Pfizer Australia Pty Ltd	Injection
		Tobi	Inhalation
		TOBI podhaler	Inhalation by mouth
		Tobrex	Application to the eye